Published in Cancer Weekly, December 4th, 2001
Several investigations of fenretinide, a retinoid, are now underway in order to establish its efficacy for treating solid tumors. The authors of an Italian study have announced fenretinide (HPR) attacks neuroblastoma-stimulated angiogenesis and endothelial cell proliferation by means of direct and indirect approaches.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.